Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
 3 Months Ended 9 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
REVENUES        
Neurometric Services $ 26,100 $ 25,900 $ 110,400 $ 83,300
OPERATING EXPENSES        
Cost of neurometric services revenues 5,200 38,800 72,100 105,800
Research 20,700 53,100 92,900 156,400
Product development 376,100 376,800 1,050,500 705,400
Sales and marketing 105,600 83,400 290,500 254,900
General and administrative 533,100 653,200 1,523,700 1,863,700
Total operating expenses 1,040,700 1,205,300 3,029,700 3,086,200
OPERATING LOSS (1,014,600) (1,179,400) (2,919,300) (3,002,900)
OTHER INCOME (EXPENSE)        
Interest expense, net (1,300) (183,300) (2,900) (1,213,600)
Gain on extinguishment of debt 0 0 1,105,200 556,300
Financing fees 0 30,500 0 (62,200)
Offering costs 0 0 0 (2,500)
Loss on derivative liabilities 0 0 0 (97,600)
Total other expense (1,300) (152,800) 1,102,300 (819,600)
LOSS BEFORE PROVISION FOR INCOME TAXES (1,015,900) (1,332,200) (1,817,000) (3,822,500)
Provision for income taxes 1,800 0 4,300 800
LOSS FROM CONTINUING OPERATIONS (1,017,700) (1,332,200) (1,821,300) (3,823,300)
Loss from discontinued operations (1,100) (1,800) (4,400) (15,200)
NET LOSS $ (1,018,800) $ (1,334,000) $ (1,825,700) $ (3,838,500)
BASIC AND DILUTED NET LOSS PER SHARE        
From continuing operations (in dollars per share) $ (0.01) $ (0.03) $ (0.02) $ (0.17)
From discontinued operations (in dollars per share) $ 0.00 $ 0.00 $ 0.00 $ 0.00
Combined Net Loss (in dollars per share) $ (0.01) $ (0.03) $ (0.02) $ (0.17)
WEIGHTED AVERAGE SHARES OUTSTANDING        
Basic and Diluted (in shares) 100,573,956 42,691,256 98,546,223 22,336,772